Results 191 to 200 of about 72,605 (256)

Oral Health—Head and Neck Cancers: Addressing Confounding Through Negative Control and Quantitative Bias Analyses

open access: yesCommunity Dentistry and Oral Epidemiology, Volume 54, Issue 3, Page 347-353, June 2026.
ABSTRACT Objectives While there are plausible biological explanations for the association between oral health and head and neck cancers (HNC), existing studies have yielded conflicting results. A key concern is that these associations are influenced by mediators, unmeasured risk factors, and biases. To address this, a negative control exposure was used
P. K. Elango   +5 more
wiley   +1 more source

Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system

open access: yesHistopathology, Volume 88, Issue 7, Page 1295-1314, June 2026.
Changes and new entities in the 6th edition WCT of the digestive system, including structural, molecular, and diagnostic updates to standardize terminology and improve clinical relevance. Epithelial tumours are organized by site; neuroendocrine, mesenchymal and haematolymphoid tumours have dedicated chapters, with refined grading, redefined ...
Mark J Arends   +48 more
wiley   +1 more source

Human papillomavirus‐associated adenoma of the anorectum

open access: yesHistopathology, Volume 88, Issue 7, Page 1459-1463, June 2026.
Aims Human papillomavirus (HPV) is the most common sexually transmitted disease in the United States. HPV‐associated invasive anorectal adenocarcinoma has been previously described. In this study, we report the clinicopathological features of three HPV‐associated anorectal adenomas.
Paula Toro   +3 more
wiley   +1 more source

Cancer detection using human papillomavirus self‐sampling targeting long‐term non‐attenders in an organized cervical screening program

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2729-2735, 15 May 2026.
What's New? The strategy to offer self‐sampling for human papillomavirus testing to increase cervical cancer screening attendance among long‐term non‐attenders has been mostly validated in randomized trials. This real‐life implementation of self‐sampling for long‐term non‐attenders to the routine screening program in the capital region of Sweden ...
K. Miriam Elfström   +3 more
wiley   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

open access: yesMolecular Oncology, Volume 20, Issue 5, Page 1098-1110, May 2026.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor   +2 more
wiley   +1 more source

A Systematic Review and Meta‐Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Tumour mutation burden (TMB) is an emerging pan‐cancer biomarker with predictive value for immune checkpoint inhibitor (ICI) outcomes, yet evidence is inconsistent due to methodological variability and cut‐off thresholds. This systematic review and meta‐analysis evaluated the impact of TMB on overall survival (OS) and progression ...
Aijia Meng   +8 more
wiley   +1 more source

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

open access: yesCancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from
Tae Min Kim   +25 more
wiley   +1 more source

Round Up: Human papillomavirus (HPV)

open access: yesReproductive Health Matters, 2011
openaire   +1 more source

Pap testing and high‐risk HPV testing for women aged 65 years and older with surgical pathology follow‐up

open access: yesCancer Cytopathology, Volume 134, Issue 5, May 2026.
ABSTRACT Background Current professional guidelines recommend discontinuing Papanicolaou (Pap) test screening in women aged 65 years and older who have had adequate prior negative testing. However, limited data exist on Pap test performance and histologic outcomes in this population.
Timothy G. Ramseyer   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy